Controversies Involving the Systemic Treatment for Metastatic Prostatic Cancer
DOI:
https://doi.org/10.32635/2176-9745.RBC.1987v33n1.3190Palavras-chave:
Neoplasias da Próstata, Metástase Neoplásica, Terapia NeoadjuvanteResumo
In the United States, 1987 estimates of cancer incidence by site indicate that prostatic cancer is equal to lung cancer as the first in incidence in adult males. Over 90,000 new cases are diagnosed and between 25-30,000 patients die of this disease each year. While early prostatic cancer is a surgically curable disease, the majority of patients present with widely metastatic cancer, where the main objective of treatment is palliation.
Downloads
Referências
Silberberg E, Lubera J - Cancer statistics, 1987. Ca - A Cancer Journal for Clinicians, 1987; 37(1):2-19. DOI: https://doi.org/10.3322/canjclin.37.1.2
Huggins C, Hodges CV – Studies in prostatic cancer. I.The effect of castration, estrogens and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Can Res, 1941; 1:293.
Byar DP — The Veteran's Administration Cooperative Urological Research Group's Studies of Cancer of the Prostate. Câncer, 1973; 32(5): 1126-1130. DOI: https://doi.org/10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C
Byar DP - Review of the Veteran's Administration studies of cancer of the prostate and new resuits concerning treatment of stage I and II tumors, in: Pavone-Malacuso M, Smith PH, Edsmyr F (eds): Bladder Tumors and Other Topics in Urological Oncology. New York. Plenum Publishing, 1980:471492. DOI: https://doi.org/10.1007/978-1-4613-3030-1_93
Byar DP, HUSER, BAILAR JCIII — Anexponential model relating censored survival data and concomitant Information for prostaticcancer patients JNCI 1974: 52(2):32T326. DOI: https://doi.org/10.1093/jnci/52.2.321
Goldie JH, Coldmân AJ, Gudauskas GA — Rationale for the use of non-cross-resistant chemotherapy. Câncer Treat Rep, 1982; 66:439-449.
Goldie JH, Coldman AJ — A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979-63: 1727-1733.
Norton L, Simon R - Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep, 1977; 61: 1307-1317.
Canetta R, Florentine S, Hunter H, Lenaz L — Megestrol acetate. Cancer Treat Rev, 1983: 10: 141-57. DOI: https://doi.org/10.1016/0305-7372(83)90029-4
Geller J, Albert J, Yen S - Treatment of advanced cancer of the prostate with megestrol acetate. Urology, 1978; 12(5): 537-41. DOI: https://doi.org/10.1016/0090-4295(78)90467-3
Rost A, Schmidt-Goliwitzer M, Hartelman W, Bronig W — Cyprosterone acetate, testosterone, LH, FSH, and prolactin leveis in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer Prostate, 1981; 2: 315-22. DOI: https://doi.org/10.1002/pros.2990020310
Bracci U - Antiandrogens in the treatment of prostatic cancer. EurUrol, 1979 5: 303-6. DOI: https://doi.org/10.1159/000473139
Treter KJ, Gtnes B, Hannestad R - Treatment of prostatic carcinoma with cyproterone acetate. Scan J Urol Nephrol, 1978:12:115-8. DOI: https://doi.org/10.3109/00365597809179976
Giuliani L, Pescatores D, Giberti C, MartorànaG, NotteG - Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy - 5-year follow-up. Eur Urol, 1980; 6: 145-8. DOI: https://doi.org/10.1159/000473313
Jacobi GH, Altwein JE, Kurth KH, Barting R, Hohenfellner R – Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase II randomized trial. Br J Urol, 1980; 52: 208-25. DOI: https://doi.org/10.1111/j.1464-410X.1980.tb02961.x
Geller J, Albert J, Yen SSC, Geller S, Loza D — Medicai castration of males with megestrol acetate and small doses of diethylstilbestrol. J Clin Endo Metab, 1981; 52: (3): 576-80. DOI: https://doi.org/10.1210/jcem-52-3-576
Peets E, Hensen F, Neri R - Effects of a novel nonsteroidal antiandrogen SCH 13521 on testosterone disposition in rats. Fed Proc, 1973; 32: 759.
Geller J, Albert J, Nachtschein DA, Loza D, Geller S - The effects of Flutamide on total DHT and nuclear DHT leveis in the human prostate. Prostate, 1981; 2: 309-14. DOI: https://doi.org/10.1002/pros.2990020309
Sufrin G, Coffey DS — Mechanisms of action of a new nonsteroidal antiandrogen: Elutamide. Invest Urol, 1975:15: 429-34.
Peets E, Hensen F Neri R, Tabachnick I — Effects of nonsteroidal antiandrogen SCH 13521 on testosterone disposition in rats. Fed Proc, 1973; 32: 759.
Hellman L, Brodiow HL, Freed S et al - The effect of Flutamide on testosterone metabolism and plasma leveis of androgens and gonadotropins. J Clin Endocrinol Metab, 1977: 45: 1224. DOI: https://doi.org/10.1210/jcem-45-6-1224
Varkarakis MJ, Kirdani RY, Yamanaka H, Murphy GP, Sandberg AA — Prostatic effects of a nonsteroidal antiandrogen. Inves Urol, 1975; 12:275-84.
Sogani P, Vagaiwala MR, Whitmore WF — Experience with Flutamide in patients with advanced prostatic câncer without prior endocrine therapy. Cancer, 1984; 54: 744-50. DOI: https://doi.org/10.1002/1097-0142(1984)54:4<744::AID-CNCR2820540426>3.0.CO;2-P
Schally AV, Comaru-Schally AM, Redding TW - Antitumor effects of analogues of hypothalamic hormones in endocrine-dependent cancers (41797). Proc Soc Exp Biol Med, 1984; 175: 259-81. DOI: https://doi.org/10.3181/00379727-175-41797
Schally AV, Kastin AJ, Arimura A - FSH-releasing hormone and LH-releasing hormone. Vitam Horm, 1972: 30: 83-164. DOI: https://doi.org/10.1016/S0083-6729(08)60795-5
Schally AV, Arimura A, Coy DH — Recent approaches to fertility control based on derivatives of LH-RH. Vitam Horm, 1980; 38: 257-323. DOI: https://doi.org/10.1016/S0083-6729(08)60487-2
Monahan MW, Amoss MS, Anderson HA, Vale W - Synthetic analogs of the hypothalamic luteinizing hormones releasing factor with increased agonist or antagonist properties. Biochemistry, 1973; 12: 4616-20. DOI: https://doi.org/10.1021/bi00747a012
Coy DH, Vilchez-Martinez JA, Loy EJ, Schally AV - Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutes in position 6. J Med Chem, 1976; 19: 423-8. DOI: https://doi.org/10.1021/jm00225a018
Fujino M, Kobayashi S, Obayashi M et al — Structure-activity relationships in the C-terminal part of luteinizing hormone releasing hormone (LHRH). Biochem Biophys Res Commun, 1972; 49: 863-9. DOI: https://doi.org/10.1016/0006-291X(72)90490-1
Eisenberger MA, 0'dwyer PJ, Friedman MA — Gonadotropin hormone releasing hormone analogues: A new therapeutic approach for prostatic carcinoma. J Clin Oncol, 1986: 4: 414-424. DOI: https://doi.org/10.1200/JCO.1986.4.3.414
Smith JA — New methods of endocrine management of prostatic cancer. J Urol 1987: 137: 1-10. DOI: https://doi.org/10.1016/S0022-5347(17)43855-9
The Leuprolide Study Group - Leuprolide versus diethylstilbestrol for metastatic prostate câncer. N EngI J Med; 1984: 311 (20): 1281-6. DOI: https://doi.org/10.1056/NEJM198411153112004
EORTC Study 30805 - Prelimary results present at the 2nd International Symposium on prostatic cancer. Paris, France, 1986.
EIlis WJ, Isaacs JT — Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. Cancer Res,1985; 45: 6041-6050.
Robinson MRG, Thomas BS — Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. British Med J 1971; 4: 391-394. DOI: https://doi.org/10.1136/bmj.4.5784.391
Klotz LH - Intermittent endocrine therapy for advanced prostate cancer. Proc AUA, 1987: (abstract) 933 pp. 352A. DOI: https://doi.org/10.1016/S0022-5347(17)76142-3
Labrie F Dupont A, Belanger A - Complete androgen blockade for the treatment of prostate cancer. In: DeVita VT, Hellman S, Rosenberg SH, eds. Important Advances in Oncology. Philadelphia JB Lippincott, 1985.
Eisenberger MA.Simon R, O'Dwyer PJ, Wíttes RE, Friedman MA Reevaluation of non hormonal cytotoxic chemotherapy for the treatment of prostatic cancer. J Clin Oncol, 1985; 3: 827-841. DOI: https://doi.org/10.1200/JCO.1985.3.6.827
Slack NH, Mittleman A, Brady MF — The importance of the stable disease category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer, 1980: 46: 2393-2402. DOI: https://doi.org/10.1002/1097-0142(19801201)46:11<2393::AID-CNCR2820461115>3.0.CO;2-6
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
